Benchmarking of a checklist for the identification of familial risk for breast and ovarian cancers in a prospective cohort.


Journal

The breast journal
ISSN: 1524-4741
Titre abrégé: Breast J
Pays: United States
ID NLM: 9505539

Informations de publication

Date de publication:
05 2019
Historique:
received: 14 08 2018
revised: 16 08 2018
accepted: 22 08 2018
pubmed: 7 4 2019
medline: 27 12 2019
entrez: 7 4 2019
Statut: ppublish

Résumé

The detection of deleterious germline mutations in BRCA1 and BRCA2 considerably influences the clinical management of healthy and diseased carriers. Therefore, the identification of persons at risk who could uptake genetic counseling and testing is pivotal. We developed a checklist with validated criteria to improve the identification, and prospectively evaluate the incidence, of familial cancer history in 5091 breast cancer patients. The rate of 30.4% of patients at high genetic risk underpins the demand for care in risk identification and counseling. The easy-to-use instrument promotes the implementation and dissemination of risk counseling by physicians.

Identifiants

pubmed: 30953388
doi: 10.1111/tbj.13257
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
BRCA2 Protein 0
BRCA2 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

455-460

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Kerstin Rhiem (K)

Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany.

Hans-Joachim Bücker-Nott (HJ)

Medical Association Westphalia Lippe, Hagen, Germany.

Martin Hellmich (M)

Institute of Medical Statistics and Computational Biology (IMSB), Köln, Germany.

Holger Fischer (H)

Klinik für Senologie Evangelische Kliniken Gelsenkirchen, Gelsenkirchen, Germany.

Beyhan Ataseven (B)

Department of Obstetrics and Gynecology, Kliniken Essen-Mitte, Gynäkologie, University Hospital, LMU Munich, Munich, Germany.

Christine Dittmer-Grabowski (C)

Kliniken Essen-Mitte, Senologie, Essen, Germany.

Kunibert Latos (K)

Klinik für Gynäkologie und Geburtshilfe, Katharinen-Hospital Unna, Unna, Germany.

Volker Pelzer (V)

Brustzentrum GFO Kliniken Bonn-Betriebstätte St. Marien, Bonn, Germany.

Manuela Seifert (M)

Abteilung für Senologie, Städtisches Klinikum Solingen, Solingen, Germany.

Andrea Schmidt (A)

Brustzentrum Mühlheim-Oberhausen, Oberhausen, Germany.

Daniela Rezek (D)

Kooperatives Brustzentrum am Marien-Hospital Wesel, Wesel, Germany.

Ulrich Groh (U)

Brustzentrum Bad Nauheim, Bad Nauheim, Germany.

Wolfgang Meinerz (W)

Brustzentrum Paderborn, Paderborn, Germany.

Dirk Crommelinck (D)

Brustzentrum Luisenkrankenhaus Aachen, Aachen, Germany.

Eric Hahnen (E)

Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany.

Simone Wesselmann (S)

German Cancer Society, Berlin, Germany.

Rita Katharina Schmutzler (RK)

Center for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH